โรคเบาหวาน (Diabetes)

Diabetes: Cao YZou S, et al., “Hypoglycemiic activity of Baker’s yeast B-glucan in obese/type 2 diabetic mice and the underlying mechanism,” Mol Nutr Food Res, PMID:27396408  DOI:10.1002/mnfr.201600032 , July 10, 2016. Quote: “B-Glucans have been shown to reduce the risk of obesity and diabetes. …pure B-glucan (BYGlc) was a linear Beta-(1,3) glucan.. It was first found that the oral administration of pure B-glucan into T2D and DIO mice significantly down-regulated the blood glucose through suppressing SGLT-1 expression in intestinal mucosa. Meanwhile pure B-glucan promoted glycogen synthesis and inhibited fat accumulation in the liver… and depressed pro-inflammatory cytokines.”

Diabetes – Silva VO, Lobato RV, et al, “B-Glucans (Saccharomyces cereviseae) Reduce Glucose Levels and Attenuate Alveolar Bone Loss in Diabetic Rats with Periodontal Disease,” PLoS One, Aug 20;10(8):e0134742. PMID 26291983: PMC4546386, 2015. Quote:…oral ingestion of β-glucans isolated from Saccharomyces cereviseae … reduced the amount of alveolar bone loss in animals with periodontal [gum] disease in both the diabetic and non-diabetic groups). β-glucans reduced blood glucose, cholesterol and triacylglycerol levels in diabetic animals, both with and without periodontal disease. It was concluded that treatment with β-glucans has beneficial metabolic and periodontal effects in diabetic rats with periodontal disease.

Diabetes – Karmuthil-Melethil S, Sofi MH, etc, “TLR2- and Dectin 1-associated innate immune response modulates T-cell response to pancreatic B-cell antigen and prevents type 1 diabetes;” Diabetes 2015 Apr;64(4):1341-57. PMID: 25377877 PMCID:PMC4375080. Quote:“These results show that zymosan [containing beta glucan] can be used as an immune regulatory adjuvant for modulating the T-cell response to pancreatic B-cell-Ag [antigen] and reversing early-stage hyperglycemia in Type 1 Diabetes.” [hyperglycemia=high blood sugar glucose]

Diabetes – Karumuthil-Melethil S, Gudi R, etc. “Fungal B-glucan, a Dectin-1 ligand, promotes protection from type 1 diabetes by inducing regulatory innate immune response.” J Immunol, 2014 Oct 1;193(7):3308-21, doi;. PMID:25143443; PMCID:PMC4170060. Quote: ” Studies using  B-glucans and other Dectin 1 binding components have demonstrated the potential of these agents in activating the immune cells for cancer treatment and controlling infections. …In this study, we show that the β-glucan from Saccharomyces cerevisiae induces the expression of immune regulatory cytokines (IL-10, TGF-β1, and IL-2) and a tolerogenic enzyme (IDO) in bone marrow-derived dendritic cells as well as spleen cells.NOD mice with low-dose β-glucan resulted in a profound delay in hyperglycemia, and this protection was associated with increase in the frequencies of Foxp3(+), LAP(+), and GARP(+) T cells.  …the innate immune response induced by low-dose B-glucan is regulatory in nature and can…modulate T cell response to B cell Ag  for inducing an effective protection from Type 1 Diabetes. Note: B cell Ag (antigen) receptors mediate different types of signals between immature B cells and mature B cells

Diabetes: Francelino A, Vieira L, Vasques A, “Effect of Beta-Glucans in the Control of Blood Glucose Levels of Diabetic Paients: A Systematic Review.” Nutr Hosp, 1;31(n01):170-177, 2014 Jan; Quote…the ingestion of BGs [beta- glucans] was efficient in decreasing glucose levels of diabetic patients.”

Diabetes – Zechner-Krpan V, Petravic-Tominac V, GrBa Slobodan, Pnaikota-Krbavcic I, Vidovic L, “Biological Effects of Yeast B-Glucans,”Agriculturae Conspectus Scientificus, 2010, Vol 75, No.4 (149-158). Quote: “Immunomodulation by B-glucan, both in vitro and in vivo, inhibits cancer cell growth and metastasis and prevents bacterial infection. In humans, dietary B-glucan lowers blood cholesterol, improves glucose utilization by body cells and also helps wound healing.”

Diabetes: Chen J, Raymond K, “Beta-glucans in the treatment of diabetes and associated cardiovascular risks,” Vascular Health Risk Management, 4(6): 1265-1272; PMCID:PMC2663451; Dec 2008. QuoteManagement of diabetes includes: control of blood glucose level and lipids; and reduction of hypertension. Dietary intake of beta-glucans has been shown to reduce all these risk factors to benefit the treatment of diabetes and associated complications.  In addition, beta-glucans also promote wound healing and alleviate ischemic heart injury.”

Diabetes: Kida K, Inoue T, Kaino Y, Goto Y, Ikeuchi M, Ito T, Matsuda H, Elliott RB. “An immunopotentiator of beta-1,6;1,3 D-glucan prevents diabetes and insulitis in BB rats.”  Dept of Pediatrics, Ehime U Sch of Med, Japan; Diabetes Res Clin Pract 17(2):75-9, PMID 1425150; Aug 1992. Quote: The intravenous administration of 1 mg kg- 1 week- of beta-1,6;1,3 D-glucan from the age of 4 weeks decreased the cumulative incidence of diabetes from 43.3% to 6.7% and also incidence of insulitis from 82.4% to 26.3% at the age of 20 weeks. …These data indicate that immunopotentiators [beta-1,6;1,3 D-glucan] could modulate the autoimmune mechanisms directed to pancreatic islets and inhibit the development of diabetes in BB rats.”

Diabetes / Glucose Control: Pola P, “Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms,”U.S. Patent Application 20030017999, January 23, 2003. “.beta-1,3-D-glucan has proved effective not only in preventing lipid metabolism disorders, but also in stimulating immune defenses, in preventing onset of tumors and in controlling serum glucose.

Diabetes: Carrow, D.J.; “Beta-1,3-glucan as a Primary Immune Activator,” Townsend  Letter; June 1996. Quote: “The following list includes benefits from the use of Beta 1,3-glucan supplementation: …people with chronic degenerative disorders such as diabetes or chronic inflammation. …

Diabetes: Lang C.H., Dobrescu C.; “Interleukin-1 induced increases in glucose utilization are insulin mediated.” Life Sciences; 45(22):2127-34. 1989.

Diabetes: Sherwood. E.R., et al., “Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan,” International  Journal of Immunopharmacology.; 9:(3):261-267. 1987.

Diabetes : DiLuzio N.R. and Williams D.L.,  “ The Roll of Glucan in the Prevention and Modification of Microparasitic Diseases;” in Chemical Regulation of Immunology in Veterinary Medicine, Alan R. Liss, Inc.; pp. 443-456. 1984. Quote: “Mindful of the extremely high rate of atherosclerotic complications and the extraordinary requirements for antioxidants  in diabetic patients, the use of beta –1,3 glucan becomes an obvious adjunct for improved lifestyle under these conditions.”

Diabetes – Periodontal Disease: Silva Vde O1, et al, “B-Glucans (Saccharomyces cereviseae) Reduce Glucose Levels and Attenuate Alveolar Bone Loss in Diabetic Rats with Periodontal Disease.” PLoS One; 10(8):e0134742; Aug 20; 2015. Quote: “β-glucans reduced the amount of alveolar bone loss in animals with periodontal disease in both the diabetic and non-diabetic groups.”


 

Comments are closed.